Advanced prostate cancer frequently escapes androgen receptor pathway inhibition through mechanisms including restored androgen signaling, lineage plasticity, and metabolic adaptation. Neuroendocrine prostate cancer (NEPC) can emerge as an androgen-insensitive lineage and has mostly been studied in the context of its transcriptional and epigenetic reprogramming. However, evidence increasingly supports the requirement for metabolic rewiring across a variety of pathways in the transition to NEPC. In this issue of the JCI, Wei et al. demonstrated that serotonin metabolism regulated by tryptophan hydroxylase 1 (TPH1) stabilizes the plastic state of NEPC by supporting serotonin-based posttranslational modification (serotonylation) of mTOR and FOXM1/E2F1 activation. These findings position TPH1 as both a neuroendocrine marker and a functional mediator of hormone therapy resistance. Because metabolic escape can involve many pathways, biomarker-guided patient selection will be required for translating these findings to an intervention. Accordingly, targeting TPH1 may delay or reverse therapy-induced NEPC in selected patients.
Kevin Holm, Neil A. Bhowmick
Drivers of hormone therapy escape.